Eric J. Avery
Impact in
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 11
- Chronic Lymphocytic Leukemia Research 10
-
- Lymphoma Diagnosis and Treatment 6
- Co-authors
- Wojciech Jurczak (10 shared papers)Javier de la Serna (10 shared papers)Sean Dolan (10 shared papers)Abraham Jacob (10 shared papers)Martin Šimkovič (10 shared papers)Paolo Ghia (10 shared papers)Daniel Lysák (10 shared papers)Andrzej Pluta (9 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)HemaSphere (2 papers)Blood (1 paper)American Journal of Hematology (1 paper)Anticancer Research (1 paper)
- Partner nations
- United StatesSouth KoreaItaly
In The Last Decade
Eric J. Avery
16 papers receiving 439 citations
Eric J. Avery's Hit Papers
Peers
Comparison fields: 5 of 49
- Genetics 347
- Pathology and Forensic Medicine 280
- Hematology 121
- Immunology 111
- Gastroenterology 20
Countries citing papers authored by Eric J. Avery
This map shows the geographic impact of Eric J. Avery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Avery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Avery more than expected).
Fields of papers citing papers by Eric J. Avery
This network shows the impact of papers produced by Eric J. Avery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Avery. The network helps show where Eric J. Avery may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric J. Avery, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia Hit paper breakdown → | 2020 | 252 |
| 2 | 2022 | 65 | |
| 3 | Transgender Health and HIV Prevention: Needs Assessment Studies from Transgender Communities Across the United States | 2006 | 35 |
| 4 | 2019 | 21 | |
| 5 | 2009 | 18 | |
| 6 | 2021 | 15 | |
| 7 | 2021 | 13 | |
| 8 | 2016 | 7 | |
| 9 | 2020 | 6 | |
| 10 | 2020 | 5 | |
| 11 | 2022 | 3 | |
| 12 | 2019 | 2 | |
| 13 | 2005 | 1 | |
| 14 | 2022 | 1 | |
| 15 | 2020 | 1 | |
| 16 | 2019 | 1 | |
| 17 | 2021 | 0 |
About Eric J. Avery
Eric J. Avery is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Pulmonary and Respiratory Medicine and Oncology, having authored 17 papers that have together received 446 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (6 papers), Chronic Myeloid Leukemia Treatments (6 papers), Advanced Breast Cancer Therapies (3 papers), Nail Diseases and Treatments (1 paper), Lung Cancer Diagnosis and Treatment (1 paper), Breast Cancer Treatment Studies (1 paper) and Medical Imaging Techniques and Applications (1 paper). The work is most often cited by research in Genetics (347 citations), Pathology and Forensic Medicine (280 citations), Hematology (121 citations), Immunology (111 citations) and Gastroenterology (20 citations). Eric J. Avery has collaborated with scholars based in United States, South Korea and Italy. Frequent co-authors include Wojciech Jurczak, Javier de la Serna, Sean Dolan, Abraham Jacob, Martin Šimkovič, Paolo Ghia, Daniel Lysák, Andrzej Pluta, Árpád Illés and Małgorzata Wach. Their work appears in journals such as Journal of Clinical Oncology, HemaSphere, Blood, American Journal of Hematology and Anticancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.